1,814,408 Shares in Stoke Therapeutics, Inc. $STOK Bought by Jupiter Topco LLC

Jupiter Topco LLC bought a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the 2nd quarter, HoldingsChannel reports. The firm bought 1,814,408 shares of the company’s stock, valued at approximately $59,358,000.

Other institutional investors have also bought and sold shares of the company. AQR Capital Management LLC raised its position in shares of Stoke Therapeutics by 1.2% in the 4th quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock worth $935,000 after acquiring an additional 354 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of Stoke Therapeutics by 22.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,951 shares of the company’s stock valued at $64,000 after purchasing an additional 359 shares during the period. Strs Ohio boosted its position in shares of Stoke Therapeutics by 9.4% during the 4th quarter. Strs Ohio now owns 7,000 shares of the company’s stock valued at $222,000 after purchasing an additional 600 shares in the last quarter. First Trust Advisors LP boosted its position in shares of Stoke Therapeutics by 0.5% during the 1st quarter. First Trust Advisors LP now owns 163,459 shares of the company’s stock valued at $5,322,000 after purchasing an additional 780 shares in the last quarter. Finally, Kestra Advisory Services LLC acquired a new stake in Stoke Therapeutics during the fourth quarter worth approximately $26,000.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on STOK. Canaccord Genuity Group lowered their target price on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a report on Friday, August 21st. They set an “overweight” rating and a $40.00 price target on the stock. Wedbush raised their price objective on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Guggenheim reiterated a “buy” rating and issued a $60.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Finally, BTIG Research reiterated a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a research report on Monday, May 11th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.25.

Insiders Place Their Bets

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 2,861 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $91,637.83. Following the completion of the sale, the general counsel owned 21,225 shares in the company, valued at approximately $679,836.75. This trade represents a 11.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Edward M. Md Kaye sold 12,567 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $402,521.01. Following the transaction, the director directly owned 124,557 shares in the company, valued at approximately $3,989,560.71. This represents a 9.16% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 30,623 shares of company stock valued at $953,765. Corporate insiders own 9.60% of the company’s stock.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $32.59 on Friday. The company has a fifty day moving average price of $31.21 and a 200-day moving average price of $32.26. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -9.76 and a beta of 1.20. Stoke Therapeutics, Inc. has a 1 year low of $18.80 and a 1 year high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The firm had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. On average, research analysts anticipate that Stoke Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.